Synaptogenix: Funding, Investors & Team (Sep 2026)
Bryostatin-1 and its analogs are being used by clinical-stage biotech business Synaptogenix to find and provide tailored treatments for developmental and neurodegenerative illnesses. Due to its high potential and multi-modal efficacy, the business has focused on bryostatin-1. By activating protein kinase C (PKC), bryostatin-1 promotes amyloid-degrading enzymes, synaptic growth factors, and prevents Tau from transforming into neurofibrillary tangles.
Synaptogenix has raised $15.0M across 1 funding round on record, the most recent an undisclosed round of $15.0M announced in Nov 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Synaptogenix Company Profile and Key Stats
Latest funding round on record: Nov 2022.
Synaptogenix Funding Rounds
Synaptogenix Founders and Leadership Team
Contact details for the Synaptogenix team: 1 of 1 has an email address on file.
Start 14-day free trial →Synaptogenix Funding Compared to Other Biotechnology Startups
Synaptogenix's latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Synaptogenix in Biotechnology and New York
Companies Similar to Synaptogenix
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Synaptogenix Funding FAQs
What does Synaptogenix do?
Bryostatin-1 and its analogs are being used by clinical-stage biotech business Synaptogenix to find and provide tailored treatments for developmental and neurodegenerative illnesses. Due to its high potential and multi-modal efficacy, the business has focused on bryostatin-1. By activating protein kinase C (PKC), bryostatin-1 promotes amyloid-degrading enzymes, synaptic growth factors, and prevents Tau from transforming into neurofibrillary tangles.
How much funding has Synaptogenix raised?
Synaptogenix has raised $15.0M across 1 round on record. The most recent is an undisclosed round of $15.0M announced in Nov 2022.
When did Synaptogenix last raise funding?
Synaptogenix's most recent funding round on record is an undisclosed round of $15.0M, announced in Nov 2022.
Who is the CEO of Synaptogenix?
Alan Tuchman is listed as CEO at Synaptogenix.
Where is Synaptogenix headquartered?
Synaptogenix is based in New York, United States.
How many employees does Synaptogenix have?
Synaptogenix is in the 1-10 employee band.
How does Synaptogenix's funding compare to other Biotechnology startups?
Synaptogenix's latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Synaptogenix Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Synaptogenix is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.